Verified employee & interview reviews

JB Chemicals & Pharmaceuticals Reviews

Mumbai, Maharashtra

—/ 5

0 reviews

J.B. Chemicals & Pharmaceuticals Limited (JB Pharma), established in 1976 and headquartered in Mumbai, is one of India's fastest-growing pharmaceutical companies. Built on a foundation of ethics, integrity, and a patient-centric approach, the company has evolved into a global player with a presence in over 40 countries. It is publicly traded on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE). Recently, the company underwent a significant change in management, with Torrent Pharmaceuticals Ltd. acquiring a 48.8% equity stake and becoming the promoter as of March 2026. The company's core operations include the manufacturing and marketing of a wide range of pharmaceutical formulations, active pharmaceutical ingredients (APIs), and herbal remedies. JB Pharma maintains a dominant position in the Indian market with flagship brands such as Cilacar (hypertension), Metrogyl (anti-infective), Nicardia (cardiac care), and Rantac (gastroenterology). The organization operates across 20 therapeutic categories, including newer segments like nephrology, respiratory, virology, diabetes, and Nicotine Replacement Therapy (NRT). Manufacturing excellence is a cornerstone of JB Pharma’s success. The company operates seven state-of-the-art manufacturing facilities in Gujarat (Ankleshwar and Panoli) and Daman. these units hold over 40 global accreditations from major regulatory bodies, including the US-FDA, EU-GMP, and South Africa’s SAHPRA. Beyond domestic formulations, JB Pharma is a global leader in the lozenges segment through its Contract Development and Manufacturing Organization (CDMO) arm, which produces over 600 million units annually. Internationally, JB Pharma has a strong footprint in regulated markets like the USA, UK, and Canada, as well as emerging markets in Africa, South-East Asia, and the Middle East. It operates through wholly owned subsidiaries in South Africa (Biotech Laboratories) and Russia. In South Africa, the company is a key supplier to both public and private sectors, covering therapeutic areas like tuberculostatics and cardiovascular diseases. In Russia and the CIS region, it has maintained a presence for nearly four decades. Financially, the company reported a total revenue of INR 3,244 crores for the fiscal year 2026, representing a 9% year-on-year growth. Its Operating EBITDA stood at INR 955 crores with a healthy margin of 29.4%, while Profit After Tax (PAT) rose to INR 608 crores. Led by CEO Nikhil Chopra and a workforce of over 5,600 employees, JB Pharma continues to prioritize innovation and ESG (Environmental, Social, and Governance) goals. By integrating sophisticated technologies and focusing on affordable healthcare, JB Pharma remains committed to its purpose of spreading good health globally and enriching patient lives.